Yttrium-90 therapy and \(^{99m}\text{Tc}\) pertechnetate knee uptake measurements in the management of rheumatoid arthritis

V. Kyle, B. L. Hazleman, and E. P. Wraight

From the \(^1\)Department of Rheumatology and the \(^2\)Department of Nuclear Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ

**Summary** Twenty-eight knees with chronic arthritis and effusion were treated with intra-articular \(^{90}\text{Y}\). Synovial activity was assessed by measuring \(^{99m}\text{Tc}\) pertechnetate uptake. There was a significant difference in uptake between controls and patients. Those who had a good response to \(^{90}\text{Y}\) (15 patients) showed a significant decrease in uptake, not seen in those who failed to respond. The pattern of \(^{90}\text{Y}\) distribution was examined and appeared to correspond to areas of increased synovial activity; these patterns and their significance have not been previously reported. Factors which could help to predict response to \(^{90}\text{Y}\) are discussed.

Radioactive colloids have been used for almost 20 years in the treatment of chronic synovitis. The initial work was done with radioactive gold \(^{198}\text{Au}\) but radioactive yttrium \(^{90}\text{Y}\) is now preferred because of the greater penetration of beta radiation, the absence of undesirable gamma radiation, and probable greater retention within the joint.

Objective assessment of the effects of \(^{90}\text{Y}\) on disease activity is desirable, and can be done by measuring radioactive technetium \(^{99m}\text{Tc}\) uptake in inflamed joints. The accumulation of \(^{99m}\text{Tc}\) pertechnetate correlates with the intensity of inflammation, and the degree of activity can be assessed by joint scanning or counting.

The aims of this study were to irradiate with \(^{90}\text{Y}\) the synovium of the knee joint in patients with chronic synovitis and effusions, measure \(^{99m}\text{Tc}\) uptake before and after treatment, and try to correlate response with uptake and clinical and radiological parameters. We also studied the pattern of \(^{90}\text{Y}\) deposition and its significance.

**Patients and methods**

Twenty-two patients were selected with chronic effusion and arthritis of one or both knee joints. Thirty-three knees were studied in total. Treatment with systemic chemotherapy and repeated intra-articular injection of steroids had been ineffective, and most were candidates for surgical synovectomy. Twenty-one of the patients had classical or definite rheumatoid arthritis by ARA criteria; one had a monoarticular arthritis of the knee with chronic recurrent effusion. The mean age was 63.24 years (range 49–76 years) and 15 were female. Disease duration ranged from 1 to 29 years, with a mean of 8.86 years. Eleven patients were receiving second-line drugs or steroids at the time of treatment, and all but 3 were seropositive.

Knee uptake measurements were based on the technique of Dick et al. The patient was positioned with a 2-inch (5-cm) scintillation counter over each knee, the end of the collimator being in line with the patellar surface. 100 \(\mu\)Ci of \(^{99m}\text{Tc}\) \(\text{TcO}_4^-\) (pertechnetate) was injected intravenously. The activity measured within the field of each counter at 15 and 20 minutes was expressed as a percentage of the injected dose by reference to a phantom counted with similar geometry. Control subjects receiving pertechnetate for thyroid scans were used to establish the normal range and to calculate baseline values corrected for body weight. After baseline uptake measurements had been obtained, the effusion was tapped and 4 mCi of \(^{90}\text{Y}\) yttrium injected, the standard Amersham silicate colloid preparation being used. \(^{90}\text{Y}\) was flushed in to prevent needle track burns with 50 mg hydrocortisone to reduce any local radiation reaction within the joint. After the knee had been flexed several times to distribute the radioactive material throughout the joint cavity the limb was

Accepted for publication 11 February 1982.
Correspondence to Dr B. L. Hazleman.
Yttrium-90 therapy and $^{99m}$Tc pertechnetate knee uptake measurements

immobilised in a splint for 2 days to minimise leakage from the joint. The final distribution of activity at 48 or 72 hours was determined by scanning, with a wide energy channel set to record Bremsstrahlung. Activity distribution was assessed as ‘localised’, ‘diffuse’, or ‘mixed’. In half the patients $^{99m}$Y was injected under x-ray control to determine whether ‘localised’ distribution was due to loculation. Counting over groin and liver was done at the same time as scanning, to estimate leakage.

Sequential measurements of knee uptake in 12 cases, involving 18 treated knees, were done at intervals of 2–14 months, median 7.5 months. Clinical assessment was also carried out at least 3 monthly intervals for a minimum of 6 months. The response to $^{99m}$Y was graded as ‘good’ if there was symptomatic improvement and the knee remained effusion free.

Fig. 1 Knee uptake measurements in 10 control subjects; each point represents the mean of both knees. $y = 2.42 - 0.92x$ $r = 0.796$

Fig. 2 Uptake measurements corrected for body surface area.

Fig. 3 Serial uptake measurements following $^{99m}$yttrium therapy in those who had a good clinical response.

Fig. 4 Serial uptake measurements following $^{99m}$yttrium therapy in those who had a poor clinical response.
Fig. 7  
Uptake of yttrium concentrated in single small focus (assessed as 'localised').

The percentage increase in uptake from the predicted baseline was then calculated at 20 minutes in 20 controls and 38 knees of 22 patients. Non-parametric statistical analysis of these results by the Mann-Whitney test showed a highly significant difference in uptake between the 2 groups (p<0.001). These data are shown in Fig. 2.

Three patients (5 knees) were excluded from analysis of results, 2 because of death from unrelated causes and 1 because of a change in treatment which could have affected response. Of the remaining 28 knees (19 patients) 15 showed a 'good' response and 13 a 'poor' response to 99mTc injection. The repeat uptake values at 20 minutes decreased in all patients with a 'good' response (Fig. 3). These figures were analysed by the Wilcoxon signed rank test, and the change in uptake was significant (p<0.02). All but one of those whose clinical response was poor showed no change in uptake or a further increase; statistical analysis confirmed that these changes were not significant (Fig. 4).

The distribution of radioactivity is shown in Table 1 and does not appear to correlate with clinical response, though numbers are too small for formal

Table 1  
Clinical response and scan appearances

<table>
<thead>
<tr>
<th></th>
<th>Localised</th>
<th>Diffuse</th>
<th>Mixed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good response</td>
<td>5</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Poor response</td>
<td>4</td>
<td>5</td>
<td>4</td>
</tr>
</tbody>
</table>

Table 2  
Clinical response and radiological grading

<table>
<thead>
<tr>
<th></th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good response</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Poor response</td>
<td>3</td>
<td>7</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
Yttrium-90 therapy and $^{99m}$Tc pertechnetate knee uptake measurements

Radiological grading did not appear to be related to response, but again the numbers were too small for analysis (Table 2).

The estimated uptake counts over groin and liver at 48–72 hours were insignificant in all cases (groin range 0·3–2·5 K, mean 1·31, liver 0–1·5 K, mean 1·05, background 0·5 K).

Discussion

Increased uptake of radionuclide in inflamed joints occurs because of hyperaemia in the inflamed synovial membrane, and also increased synovial permeability in the presence of an effusion. McCarty's group demonstrated a late 'peak' of increased activity in patients with extensive joint effusions, thought to be due to $^{99m}$Tc binding to proteins in the joint fluid. Bone vascularity is also increased in inflamed joints, but joint deformity, fibrotic changes, and muscle wasting do not influence uptake. Our results show a significant difference in the percentage uptake of $^{99m}$Tc at 20 minutes in inflamed joints when compared with controls. Those patients who responded well to $^{99m}$Y showed a significant decrease in uptake. We did not observe the late 'peak' reported by McCarty et al. Presumably the alteration in uptake reflects changes in the synovial membrane which are secondary to the inflammatory process.

Intra-articular injection of radioactive colloid has an established role in the treatment of chronic synovitis and effusions. Gumpel et al. showed in 1975 that it is as effective as surgical synovectomy after 2 years, although a more recent study cast doubt on the benefit of radioactive yttrium. The destruction of inflamed synovial membrane occurs when it is irradiated by colloidal particles removed from the suspension in the joint cavity. Radioactivity seems to be concentrated in the synovial membrane; autoradiographs have shown that the cartilaginous surface is not usually affected. Kersbaumer et al., however, reported marked degenerative change in human chondrocytes after 5 mCi of $^{99m}$Y, suggesting that colloid caused cartilage necrosis, but this study was uncontrolled, and the damage could have been due to chronic inflammation. The risks from the radiation dose to lymphocytes and lymph nodes have been examined by several groups. Most groups report an increased frequency of chromosomal aberrations in circulating lymphocytes after treatment with $^{99m}$Y; immobilising patients after injection seemed to reduce this. Roberts and Gillespie, however, did not find any increase in abnormal chromosomes. There is in any case no clear evidence that such abnormalities are significant; to date there are no reported cases of leukaemia or other malignancies. Because the penetration of beta radiation is only

Fig. 8a  Localised uptake at initial treatment.

analysis. Injections under x-ray control established that there was free flow through the joint cavity even if scans subsequently showed localisation of activity. Examples of typical patterns are shown in Figs. 5–7. One patient whose scan showed marked localisation had a second injection of $^{99m}$Y because of lack of response to the first. The second scan showed diffuse distribution of colloid but with a central 'cold' area corresponding to the initial area of localised high uptake (Figs. 8a, b). There was no correlation between initial uptake values and clinical response.

Fig. 8b  Diffuse uptake on retreatment 8 months later with apparent reduced activity centrally.
a few millimetres, the risk of irradiation to bone cells around the knee appears to be minimal. The dose to inguinal lymph nodes is usually negligible,\textsuperscript{18, 20} but other groups\textsuperscript{21} reported node uptake of >10% amounting to several thousand rads. There is no relevant experience of the risks of malignancy from such doses to human lymph nodes: local irradiation of <1000 rads (equivalent to <2–3% of the injected \textsuperscript{90}Y) seems to be innocuous,\textsuperscript{22} and leakage of amounts greater than this should be avoided if possible.

Our results showed improvement in just over half the patients treated with \textsuperscript{90}Y, rather lower than in some other studies,\textsuperscript{23–24} which may be partly explained by the varying criteria used in assessment. Although some of our patients had improved within 2 months, in some no change was apparent until more than 4 months. Menkes \textit{et al.}\textsuperscript{23} showed that a poor result at 6 months was unlikely to improve but that this was not the case at 3 months. They also found that initially good results rarely deteriorated, and a good result at 6 months was likely to remain so at 2 years.

Prediction of those most likely to respond well to \textsuperscript{90}Y is unsatisfactory. Patients with marked articular damage rather than active synovitis of the knee joint are unlikely to benefit, and grades I and II radiological changes are associated with a better response.\textsuperscript{23} Two patients who failed to respond in our study had knee arthroplasty performed shortly afterwards, and in both there was extensive bony damage but little active synovitis. As only 4 patients had radiological grades III or IV, correlation of grading with response was not possible. Winfeld and Gumpel\textsuperscript{25} suggested patients with widespread active synovitis were unsuitable for \textsuperscript{90}Y in the knee, but did not find the ESR helpful in predicting outcome. Seropositivity was associated with a lower failure rate in the study by Menkes \textit{et al.},\textsuperscript{23} but as only 3 of our group were seronegative we could not confirm this. Scan distribution and disease duration did not appear to be related to response, but again numbers were too small for formal analysis. The initial 20-minute uptake value did not correlate with clinical outcome. Another possible factor affecting response is the degree of isotope retention. Numerous studies of this have been carried out.\textsuperscript{2–12} Of the 4 commonly available yttrium colloids, citrate, ferric hydroxide, resin, and silicate, all have similar retention up to 24 hours, but by 5 days only resin and silicate preparations are consistently well retained and there is considerable variation in the other 2. Although no strict quantitative assessment of retention was made, the low counts over groin and liver in our study suggest there was little leakage of colloid from the knee joint.

An interesting feature was the varying distribution of yttrium within the knee joint. There is very little published information about this; a recent study\textsuperscript{26} of 2 autoradiographs of synovial membranes of patients treated with \textsuperscript{90}Y silicate showed nonuniform blackening of the films. This was thought to be due to uneven distribution of radioactivity, reflecting varying disease activity in the synovial membrane. These workers did not think that \textsuperscript{90}Y scans could show such variation in colloid uptake in synovial membrane. Our studies suggest this is incorrect. The pattern of \textsuperscript{90}Y uptake was readily identifiable and appeared to correspond to synovial activity. This was seen particularly clearly in a case where \textsuperscript{90}Y injection was repeated after 6 months because of lack of response. The first scan showed marked localisation in the joint, but the second showed diffuse distribution of the colloid with a central 'cold' area corresponding to the initial localised area of high uptake. It could be argued that the patterns identified were due to a mechanical effect. We think this is unlikely for the following reasons. \textsuperscript{90}Y was well distributed at the time of injection, when monitored under x-ray screening. In all patients the knee was passively flexed after injection, which has been shown to result in widespread dispersal of injected fluids.\textsuperscript{57} Further studies of \textsuperscript{90}Y distribution, particularly in cases where the injection is repeated, would be of interest.

In summary, we confirmed the value of \textsuperscript{90}Y in treating some patients, although it could not be predicted which would respond. We examined in some detail the distribution pattern of \textsuperscript{90}Y, an aspect not previously discussed. Technetium uptake was useful both in confirming inflammation and in monitoring improvement after treatment.

\textbf{References}

Yttrium-90 therapy and 99mTc pertechnetate knee uptake measurements

Yttrium-90 therapy and 99MTc pertechnetate knee uptake measurements in the management of rheumatoid arthritis.

V Kyle, B L Hazleman and E P Wraight

doi: 10.1136/ard.42.2.132

Updated information and services can be found at: [http://ard.bmj.com/content/42/2/132](http://ard.bmj.com/content/42/2/132)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)